Synonyms: CK-274 | CK-3773274 | CK3773274
Compound class:
Synthetic organic
Comment: Aficamten (CK-3773274) is an orally administered cardiac myosin inhibitor that was developed by Cytokinetics as a potential treatment for hypertrophic cardiomyopathies [1-3,6]. It was designed to reduce the hypercontractility of cardiac sarcomeres that is thought to drive hypertrophy and fibrosis in heart muscle, by binding directly to a distinct and selective allosteric binding site on cardiac myosin.
|
|
Classification | |
Compound class | Synthetic organic |
IUPAC Name |
N-[(1R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl]-1-methylpyrazole-4-carboxamide |
International Nonproprietary Names | |
INN number | INN |
11544 | aficamten |
Synonyms |
CK-274 | CK-3773274 | CK3773274 |
Database Links | |
CAS Registry No. | 2364554-48-1 (source: WHO INN record) |
GtoPdb PubChem SID | 441604896 |
PubChem CID | 139331495 |
RCSB PDB Ligand | 6I6 |
Search Google for chemical match using the InChIKey | IOVAZWDIRCRMTM-OAHLLOKOSA-N |
Search Google for chemicals with the same backbone | IOVAZWDIRCRMTM |
Search PubMed clinical trials | aficamten |
Search PubMed titles | aficamten |
Search PubMed titles/abstracts | aficamten |
UniChem Compound Search for chemical match using the InChIKey | IOVAZWDIRCRMTM-OAHLLOKOSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | IOVAZWDIRCRMTM-OAHLLOKOSA-N |